Gold prices steady ahead of Fed decision; weekly weakness noted
Autolus Therapeutics (NASDAQ:AUTL) stock has reached a new 52-week low, trading at $1.53, as the company faces a challenging market environment. According to InvestingPro data, the company maintains a healthy current ratio of 10.88 and holds more cash than debt on its balance sheet, though it’s currently burning through cash rapidly. This latest price point reflects a significant downturn for the biopharmaceutical company, which has seen its stock value decrease by 72.36% over the past year. Despite the decline, analysts maintain optimism with price targets ranging from $6 to $14, significantly above current levels. Investors are closely monitoring Autolus Therapeutics as it navigates through a period of volatility and seeks to regain its footing in the competitive landscape of therapeutic innovation. For deeper insights into AUTL’s valuation and growth prospects, access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US stocks with detailed analysis and actionable intelligence.
In other recent news, Autolus Therapeutics reported a net loss of $220.7 million for the fourth quarter of 2024, an increase from $208.4 million the previous year. Despite this, the company bolstered its financial position with $588 million in cash reserves, largely due to a $600 million collaboration with BioNTech (NASDAQ:BNTX) and equity financing. Mizuho (NYSE:MFG) Securities maintained its Outperform rating on Autolus, with a consistent price target of $12.00, following the company’s fourth-quarter earnings call. The call highlighted the ongoing launch of Aucatzyl, which now has 33 U.S. treatment centers authorized, surpassing the company’s target. Truist Securities also reaffirmed its Buy rating, noting the strong demand for Aucatzyl and maintaining a price target of $11.00. Truist adjusted its price target for Autolus to $10.00, reflecting a refinement in its financial model, but continued to endorse the stock with a Buy rating. Autolus is anticipating approval decisions for Aucatzyl in the UK and Europe in the second half of 2025, along with initial pediatric data.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.